Australian Patent Office defies expectations by saying yes to gene patents

The Australian Patent Office has reversed its current examination practice in Arrowhead Research Corporation [2016] APO 70 by confirming that gene-based pharmaceuticals, namely interfering RNA (iRNA) compositions, do represent patentable subject matter in Australia.   Background In October 2015, the High Court of Australia ruled in the “Myriad decision” that isolated naturally-occurring gene sequences did